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Introduction. Staphylococcal infections are the leading cause of healthcare-associated infec-
tions globally as well as in Republic of Moldova. According to different studies – this pathogen 
is highly spreading among surgical and intensive care units’ inpatients. Making part of normal 
microbiota Staphylococcus spp. can populate skin and upper respiratory ways and as a result – it 
can be transmitted by different routes.  
An extra issue represents acquired antibacterial resistance of pathogens. The mostly common 
one is Methicillin-resistant Staphylococcus aureus (MRSA). Thus, it is very important to study 
this issue in order to detect and treat these infections faster and more efficient. Nowadays, dif-
ferent methods of bacteriological and immunological investigation, as well as new technologies 
of drug industry are available. 
Material and methods. The objective of the study was to perform an analysis of the scientific 
literature related to etiology, epidemiology, diagnostic methods and prevention measures of 
MRSA infections. The bibliographic search was performed on the evidence-based sources, on 
the mostly relevant data bases – such as PubMed, HINARI, Google Scholar and other relevant 
sources. 
Results. More studies have shown large affections within MRSA infected patients. MRSA bac-
teremia is a serious infection resulting in 20-50% 90-day mortality. Some authors do declare that 
vancomycin (VCM), the current standard therapy for MRSA, make treatment difficult. The use 
of vancomycin has been increasing since the mid-1980s, resulting in the emergence of MRSA 
with reduced susceptibility to vancomycin.  
Another paper have shown that the prevalence of S. aureus and MRSA among healthcare work-
ers (HCWs) was found to be 22.7% and 32.8% respectively. Regarding survival rate without and 
with VCM therapy, was 53.1 and 82.1% in the non-intervention and intervention groups, respec-
tively. And meanwhile one paper says the only other approved drug for treatment of MRSA 
bacteremia, daptomycin, has not been shown to be superior to VMC, another one pretends that 
linezolid could be better than VMC.  
Conclusions. Since 1980s – the first option for the treatment of invasive MRSA infections is 
the glycopeptide vancomycin, which continues to be the reference standard approach in this con-
text. Anyways it has its limitations, which makes actual necessity of developing more effic ient 
and harmless drugs.  
Based on the combined analysis of randomized controlled trials, the efficacy of linezolid should 
be better than that of vancomycin in the treatment of infections caused by MRSA, but conclu-
sions still need to be further validated by more well-designed randomized controlled trials of a 
large sample. 
 
 
 
